# Codex Contribution Gate Review for JPM/FAJ Submission

Manuscript reviewed:
- `paper/vt-trend-following/main.tex`
- `paper/vt-trend-following/main_v3.tex`
- `paper/vt-trend-following/body_v3.tex`
- `paper/vt-trend-following/README.md`
- `paper/vt-trend-following/experiments.md`
- `paper/vt-trend-following/results/README.md`
- `paper/vt-trend-following/reproduce_report.json`
- `paper/vt-trend-following/figures/generate_figures.py`
- `paper/vt-trend-following/figures/fig1_return_decomposition.pdf`
- `paper/vt-trend-following/figures/fig1_return_decomposition.png`
- `paper/vt-trend-following/figures/fig2_cross_asset_scatter.pdf`
- `paper/vt-trend-following/figures/fig2_cross_asset_scatter.png`
- No `cover_letter.tex` found by filename search.
- No standalone `tables_main.tex` found; the main tables are embedded in `body_v3.tex`.

## Verdict
**BORDERLINE — the paper has a real JPM/FAJ-shaped contribution, but the current submission package is not arXiv-ready because the canonical source is ambiguous, visible internal experiment tags remain in the manuscript, Figure 2 is numerically stale, and several side claims dilute the central practitioner takeaway.**

The core idea is worth preserving: a volatility-targeting rule can contain statistical trend-following exposure while still delivering a separate drawdown-insurance benefit. That is a useful practitioner message and a plausible JPM/FAJ contribution. But the manuscript in its current form still reads like a late-stage internal research draft rather than a journal submission. I would not post this version to arXiv. The needed work is not another broad empirical expansion; it is a disciplined narrowing and package-cleaning pass that makes the paper externally self-contained.

My decision rule for this gate is stricter than "are the numbers interesting?" The answer to that narrower question is yes. A manager can understand the problem, the evidence has economically meaningful magnitudes, and the proposed rule is simple enough to implement. The paper also has the right humility about alpha: it repeatedly shows that the return channel is weak or statistically fragile, then shifts attention to the drawdown channel. That is exactly the kind of framing JPM/FAJ readers can use.

The problem is that arXiv is permanent and journal editors form credibility judgments quickly. A public version that contains a stale main source, visible internal tracking labels, stale figure annotations, and table cells marked as earlier-vintage would be reputationally costly. These are not cosmetic issues. They directly affect whether an editor trusts the empirical package. A JPM/FAJ submission can survive a limited contribution if the practical message is clear and the package is clean. It is much less likely to survive visible evidence that the manuscript has not been finalized.

I therefore separate the judgment into two parts. Contribution quality: borderline-positive. Submission readiness: fail. The combined verdict is BORDERLINE because the paper should not be abandoned or redirected to a weaker venue; it should be tightened before any public posting. A one-week focused revision could plausibly move it to arXiv-ready. A new round of broad experiments would probably make it worse by adding more side claims.

## 1. Contribution Gate
- **The central claim (one sentence — what is this paper telling JPM/FAJ readers?)**

The paper should tell portfolio managers: a simple monthly `12/VIX` de-risking overlay is not merely trend following in disguise; although it mechanically embeds asset-specific momentum exposure through the leverage effect, its main economic value is drawdown insurance that largely survives removal of that momentum exposure.

That claim is visible in the current abstract, which states that the primary benefit is drawdown insurance rather than alpha generation (`body_v3.tex:8`). The introduction frames the question cleanly: whether VIX-based de-risking is simply trend following by another name (`body_v3.tex:28`), then answers by separating a Sharpe-ratio channel from a maximum-drawdown channel (`body_v3.tex:30`). The practitioner rule is also clear: use a lagged monthly `12/VIX` weight with a cap at one and a cash sleeve (`body_v3.tex:58`, `body_v3.tex:63`).

This is a stronger contribution than "another VT backtest." It reframes a common objection to volatility targeting: even if alpha is absorbed by a time-series momentum factor, investors may still value the drawdown channel. For JPM/FAJ, that is the right level of abstraction. The paper speaks to implementability, costs, allocation behavior, and risk budgeting, not only factor-model alpha.

The central contribution is also teachable. A reader should walk away with a mental model: trend following reacts to the sign of past returns; VIX-level targeting reacts to the price and quantity of fear. These signals overlap after drawdowns because volatility rises when prices fall, but they are not the same object. That distinction explains why a factor regression can absorb alpha while the drawdown profile remains attractive. This is the phrase-level idea that should govern the title, abstract, first figure, and conclusion.

The current paper sometimes obscures that teachable idea by adding too much machinery. The GJR-GARCH cross-section is useful as mechanism evidence, but it is not what most JPM/FAJ readers will implement. The large configuration search is useful as a robustness check, but it is not the paper's reason to exist. The international table is useful as external validity, but it should support the insurance interpretation rather than become a second paper about global VIX spillovers. The author should deliberately choose a hierarchy: rule first, economic channel second, statistical mechanism third, robustness last.

- **Novelty relative to cited literature**

The relevant literature is mostly covered, but not yet completely positioned. The manuscript cites Moreira and Muir through the volatility-managed portfolio literature (`body_v3.tex:26`, `body_v3.tex:640`), Cederburg et al. as the utility critique (`body_v3.tex:26`, `body_v3.tex:610`), Moskowitz/Ooi/Pedersen as the time-series momentum benchmark (`body_v3.tex:26`, `body_v3.tex:646`), and Hurst/Ooi/Pedersen for the long managed-futures record (`body_v3.tex:26`, `body_v3.tex:631`). It also uses a recent working paper as the direct interlocutor for the alpha-absorption claim (`body_v3.tex:28`, `body_v3.tex:634`).

The missing practitioner reference is Asness/Liew or an equivalent AQR practitioner treatment of trend following and crisis alpha. Hurst/Ooi/Pedersen partly covers that territory, but the introduction currently jumps from academic TSMOM to the paper's own decomposition without fully situating the practitioner debate that JPM/FAJ readers will recognize. This is not fatal, but it is a missed positioning opportunity.

The novelty is not the `12/VIX` rule itself, nor the fact that VT can improve drawdowns. The novelty is the decomposition: "alpha absorption" is not the same as "economic value destruction." That contribution is sharp if the paper consistently treats the evidence as non-erosion of drawdown protection, not as proof of a new causal asset-pricing mechanism. The body mostly does this, especially where it cautions that point estimates above 100 percent should not be read as a stronger standalone insurance technology (`body_v3.tex:254`, `body_v3.tex:258`, `body_v3.tex:528`). This restraint is important. Without it, the paper would overclaim.

Relative to the cited literature, the most defensible positioning is incremental but useful. Moreira and Muir motivate volatility-managed portfolios; Cederburg et al. challenge their welfare value; Moskowitz/Ooi/Pedersen and Hurst/Ooi/Pedersen define the trend-following benchmark. This paper's contribution is to ask a narrower portfolio-construction question: when VT looks like trend following in factor space, what part of the investor benefit actually disappears? That question is not a pure econometric novelty, but it is a contribution for a practitioner journal if answered cleanly.

- **Practical takeaway for PMs**

There is a usable rule: monthly lagged `12/VIX`, capped at full risky exposure, with the residual held in cash (`body_v3.tex:58`, `body_v3.tex:63`). The practical message is not "expect alpha." The paper explicitly reports that alpha remains statistically insignificant after factor controls (`body_v3.tex:396`). The real message is: expect a Sharpe cost in calm markets, but drawdown protection in high-fear regimes and international risk-off episodes.

The economic magnitudes are potentially meaningful. The five-asset decomposition reports drawdown retention around or above full preservation for the core assets (`body_v3.tex:254`, `body_v3.tex:256`, `body_v3.tex:258`). The larger bootstrap table reports positive lower bounds for most assets and explicitly says no asset rejects full retention in the relevant direction (`body_v3.tex:260`). The international table reports universal MDD improvement across 13 country ETFs, with an average improvement of 24.9 percentage points (`body_v3.tex:444`, `body_v3.tex:482`). Those are the right kind of numbers for JPM/FAJ readers.

The paper should be more precise about units. It repeatedly describes the cost as a "Sharpe drag" measured in percent per year (`body_v3.tex:36`, `body_v3.tex:555`, `body_v3.tex:557`). Sharpe is unitless; foregone return is annualized percent. If the paper means annualized return cost, say that. If it means Sharpe-ratio reduction, report the unitless difference. This wording will bother careful readers because the whole paper asks them to distinguish statistical alpha from economic value.

- **Is contribution coherent — or padded with many side findings?**

Coherent, but padded. The central claim is compelling. The padding comes from adding too many supporting claims: split-sample leverage-effect correlations (`body_v3.tex:206`), continuous-versus-dummy regressions (`body_v3.tex:249`), sector boundary conditions (`body_v3.tex:437`), prediction-versus-application results (`body_v3.tex:538`), rebalancing-cost break-evens (`body_v3.tex:545`), five robustness checks (`body_v3.tex:548`), a 427-configuration search (`body_v3.tex:551`), dynamic allocation failures (`body_v3.tex:560`), and utility statements (`body_v3.tex:532`).

These are not irrelevant, but in the main paper they make the contribution look less self-contained. JPM/FAJ does not need every internal robustness trail in the body. The best version of this paper has one spine: VT embeds asset-specific trend exposure, but its drawdown channel survives removing it; the `12/VIX` rule is an implementable insurance overlay, not an alpha machine. Most additional tests should be reduced to one compact robustness paragraph or moved to an online appendix.

## 2. Identification & Rigor
- **In-sample vs OOS honesty**

The implementability language is mostly clean. The volatility target uses lagged weights (`body_v3.tex:63`), the TSMOM signal is measured through day `t-1` (`body_v3.tex:67`, `body_v3.tex:69`), and the rolling hedge beta is estimated only with prior observations (`body_v3.tex:104`). These choices address the most obvious look-ahead risk.

There are still two rigor issues. First, the orthogonalized TSMOM factor uses a full-sample projection onto the market factor (`body_v3.tex:74`, `body_v3.tex:79`). That is acceptable for attribution, but not as an implementable signal. The manuscript should explicitly keep this distinction: full-sample orthogonalization is a diagnostic decomposition, while the tradable hedge uses rolling information.

Second, the out-of-sample evidence is not strong enough to carry the paper. The sub-period section says the key result holds in an OOS 2023--2026 period (`body_v3.tex:510`), but the limitations acknowledge that this period does not contain a crisis comparable to 2008 (`body_v3.tex:564`). That is honest, but it means the main evidence remains historical and regime-dependent. For JPM/FAJ this is probably acceptable if the claim is "insurance overlay historically preserved drawdown protection," not "validated trading strategy."

- **Multiple-testing discipline**

The manuscript knows about multiple testing and invokes conservative thresholds, including the Harvey threshold for trend-following rules (`body_v3.tex:535`) and for several optimization attempts (`body_v3.tex:578`). That helps.

The problem is contribution design. A comprehensive search over 427 VT configurations appears in the discussion (`body_v3.tex:551`). Five independent robustness checks and alternative thresholds also appear in the same section (`body_v3.tex:548`). These are useful as appendix material, but in the main text they create an ex post search impression. A practitioner journal reader will ask: was the main rule selected before the search, or is the paper rationalizing the winner after seeing a large grid?

The solution is straightforward: declare one confirmatory specification in the main text, put the grid search in an appendix, and report it as robustness rather than as primary evidence. The paper should not ask a reader to treat 427 explored configurations and a simple rule as the same level of evidence.

- **Magnitudes vs noise**

The drawdown magnitudes are strong enough to matter. The core table reports SPY buy-and-hold MDD of -55.2 percent versus -26.3 percent for VT and -25.3 percent after the TSMOM hedge (`body_v3.tex:254`, `body_v3.tex:357`, `body_v3.tex:358`, `body_v3.tex:359`). The international table reports average MDD improvement of 24.9 percentage points (`body_v3.tex:482`). These are economically large.

The alpha and Sharpe evidence is weaker, and the paper should lean into that. Factor alpha is 128 bps per year but statistically insignificant (`body_v3.tex:396`). Only 2 of 13 international markets show Sharpe improvement (`body_v3.tex:446`). The bootstrap table has wide confidence intervals, including an energy-sector point estimate above 200 percent with a much lower 5th percentile (`body_v3.tex:279`) and a silver lower bound slightly below zero (`body_v3.tex:294`). This does not undermine the main non-erosion claim, but it does rule out any aggressive claim that the hedge creates a universally superior insurance technology.

The paper should also distinguish economic significance from statistical significance more explicitly. A 24.9 percentage-point average MDD reduction is economically large even if the exact decomposition ratios are noisy. A 128 bps annual alpha estimate with a t-statistic near 1.5 is not a reliable alpha claim, even if it is directionally attractive. A wide bootstrap confidence interval can still support the statement "the drawdown benefit is not erased," but it cannot support fine-grained ranking across assets. JPM/FAJ readers will accept this if the paper tells them plainly what is robust and what is not.

- **Internal consistency**

This is the main barrier to arXiv.

First, `main.tex` is explicitly marked stale and says the canonical source is `main_v3.tex` (`main.tex:2`, `main.tex:3`). But the task identifies `main.tex` as the main entry. A submission package cannot contain a stale main entry with old numbers. Either `main.tex` must become the canonical entry that inputs `body_v3.tex`, or it must be removed from the submission bundle. `main_v3.tex` correctly inputs `body_v3.tex` (`main_v3.tex:42`), but arXiv and coauthors will default to `main.tex` if it exists.

Second, visible internal experiment tags remain in the manuscript body, including the abstract and conclusion (`body_v3.tex:8`, `body_v3.tex:576`). These should not appear in a JPM/FAJ or arXiv manuscript. They can remain in comments, replication docs, or appendix source notes, but not in visible prose and table notes.

Third, Figure 2 is stale. The current body and table use average MDD improvement of 24.9 percentage points and VIX-sensitivity correlation of -0.806 (`body_v3.tex:482`, `body_v3.tex:487`, `body_v3.tex:503`). The figure generator still hard-codes the old values and annotation (`figures/generate_figures.py:143`, `figures/generate_figures.py:203`, `figures/generate_figures.py:229`). The PNG/PDF artifact also displays the old average and old correlation. This is a blocking text-figure inconsistency.

Fourth, Table 3 still carries earlier-vintage Calmar values. The source comment says the 50/50 Calmar cells retain earlier values pending recomputation (`body_v3.tex:356`), and the visible text repeats the caveat (`body_v3.tex:376`). This cannot remain in a submission. A table cell marked as pending recomputation tells reviewers the core table is not finalized.

Fifth, the BAB factor description is inconsistent. The data section says BAB is obtained from AQR (`body_v3.tex:54`), but the factor table note says BAB is proxied by an ETF spread available only from May 2011 and constrains the model to 3,740 observations (`body_v3.tex:424`, `body_v3.tex:429`). A reader cannot know whether the reported coefficients use the AQR factor, the ETF proxy, or two different samples.

## 3. JPM/FAJ-specific fit
- **Length & structure**

The compiled `main_v3.pdf` is 40 pages. That is long for JPM and still heavy for FAJ once tables, figures, and references are included. The target should be a tighter practitioner paper: one-page introduction, compact methods, three main empirical tables, two figures, short discussion, and online appendix for the rest. The current manuscript has enough content for a working paper, but too much for a first submission to JPM.

For JPM, a realistic target is about 5,000 words plus selected tables. For FAJ, about 8,000 words is more plausible, but the current draft still needs sharper narrative hierarchy. The long abstract (`body_v3.tex:8`) tries to carry nearly every result. It should be cut to the contribution, the rule, and three numbers: retained drawdown protection, international MDD improvement, and implementation cost.

- **Tone**

The tone is technically careful but not yet practitioner-ready. A JPM/FAJ reader should not see a forensic correction section in the main body (`body_v3.tex:519`). The paper should not narrate which earlier numbers could not be reproduced (`body_v3.tex:521`, `body_v3.tex:522`, `body_v3.tex:524`). That belongs in an internal audit trail or replication appendix. In the main text, use the corrected numbers and state the current design cleanly.

The paper should also reduce equation density and table-note density. Equations are necessary for the VT rule, TSMOM construction, hedge, and retention metric (`body_v3.tex:58`, `body_v3.tex:67`, `body_v3.tex:99`, `body_v3.tex:123`). The rest should be written as portfolio-management intuition: when VIX is high, reduce risky exposure; when trend signals lag reversals, the VIX-level channel can differ from momentum; the cost is foregone participation in calm markets.

- **Figures**

Figure 1 supports the take-home: Sharpe improvement is partly trend-related, drawdown protection is mostly preserved. It is the right figure for a practitioner paper. It should be cleaned visually because the small red MDD segments and labels are cramped, but the concept works.

Figure 2 is conceptually useful but numerically stale. The body caption says the dotted lines correspond to -0.048 Sharpe and 24.9 pp MDD improvement (`body_v3.tex:503`), while the figure artifact displays 28.7 pp and the old correlation. This figure should be regenerated from the same source as Table 5, not hard-coded from an earlier table.

- **Cover letter — needed for JPM and FAJ**

JPM: yes, prepare a cover letter. It should be short and practical: this paper is not another volatility-targeting performance chase; it tells managers how to interpret the overlap between VT and trend following, and why drawdown insurance can survive alpha absorption.

FAJ: yes, prepare a cover letter. It should emphasize relevance to investment practice, replicability, non-proprietary data, implementation costs, and why the paper's contribution is educational for CFA-style practitioner audiences.

No cover letter file is currently present. That is not a fatal content problem, but it is a submission-package gap.

## 4. Reframing agenda
- **Fix the canonical submission entry.** Change `main.tex` so it is no longer a stale standalone version, or remove it from the arXiv/journal bundle and make `main_v3.tex` the explicit submission source. Location: `main.tex:2`, `main.tex:3`, `main_v3.tex:42`. Why: the current package can easily compile or cite the wrong manuscript.

- **Remove all visible internal experiment tags from public prose and table notes.** Replace them with neutral source notes in an appendix or comments. Locations include `body_v3.tex:8`, `body_v3.tex:34`, `body_v3.tex:307`, `body_v3.tex:337`, `body_v3.tex:429`, `body_v3.tex:521`, `body_v3.tex:528`, `body_v3.tex:576`. Why: public-facing manuscripts should not expose internal tracking labels; this alone blocks arXiv.

- **Regenerate Figure 2 from current Table 5 values.** Update the generator and image artifacts so the average MDD line and correlation annotation match the body. Locations: `figures/generate_figures.py:143`, `figures/generate_figures.py:203`, `figures/generate_figures.py:229`, `body_v3.tex:482`, `body_v3.tex:487`, `body_v3.tex:503`. Why: a reader will immediately notice the old 28.7 pp figure versus the current 24.9 pp table value.

- **Recompute or remove the earlier-vintage Calmar cells in Table 3.** Locations: `body_v3.tex:356`, `body_v3.tex:357`, `body_v3.tex:358`, `body_v3.tex:359`, `body_v3.tex:360`, `body_v3.tex:376`. Why: pending recomputation language in a core table is incompatible with submission.

- **Resolve the BAB source and sample-size conflict.** Decide whether Table 4 uses the AQR factor or the ETF proxy, then make the data section, N row, and note agree. Locations: `body_v3.tex:54`, `body_v3.tex:424`, `body_v3.tex:429`. Why: factor-control credibility depends on exact data provenance and sample definition.

- **Rewrite the abstract and contribution paragraph around one claim.** Reduce the abstract to: problem, method, main drawdown magnitude, implementation rule, and implication. Locations: `body_v3.tex:8`, `body_v3.tex:32`, `body_v3.tex:34`, `body_v3.tex:36`, `body_v3.tex:38`. Why: the current abstract is overloaded and exposes too many audit details.

- **Move forensic revision notes out of the main text.** Locations: `body_v3.tex:519`, `body_v3.tex:521`, `body_v3.tex:522`, `body_v3.tex:524`. Why: journal readers need the final design and final evidence, not the manuscript's repair history.

- **Clarify the economic cost units.** Replace "Sharpe drag" in percent per year with either annualized return cost or unitless Sharpe-ratio change. Locations: `body_v3.tex:36`, `body_v3.tex:555`, `body_v3.tex:557`. Why: the current wording mixes return units and Sharpe units.

- **Reduce side claims to appendix status.** Keep the 427-specification search, dynamic allocation failures, prediction-versus-application result, and utility boundary as robustness or appendix material. Locations: `body_v3.tex:532`, `body_v3.tex:538`, `body_v3.tex:548`, `body_v3.tex:551`, `body_v3.tex:560`. Why: the JPM/FAJ contribution should be self-contained, not a bundle of adjacent findings.

- **Add the missing practitioner trend-following citation context.** Add Asness/Liew or an equivalent practitioner trend-following reference near the introduction and literature positioning. Locations: `body_v3.tex:26`, `body_v3.tex:38`, `body_v3.tex:631`, `body_v3.tex:646`. Why: JPM/FAJ readers will expect the paper to connect to practitioner trend-following literature, not only academic TSMOM.

- **Create a submission cover letter.** Location: new `paper/vt-trend-following/cover_letter.tex` or Markdown equivalent. Why: both target venues need a concise editorial pitch explaining the practical contribution, replication package, and why the paper is not merely an incremental VT backtest.

## 5. Recommended next step
**Major revision** → DO NOT arXiv yet; reframe per §4 first.

Highest-priority fixes before any public posting:

1. Make the submission source unambiguous and remove visible internal experiment tags.
2. Regenerate Figure 2 and remove all stale or pending table values.
3. Rewrite the abstract, introduction contribution paragraph, and conclusion around the single drawdown-insurance claim.
4. Resolve the BAB data/sample conflict and sample-period presentation.
5. Prepare a short JPM/FAJ cover letter and a clean data/code availability statement.

After those fixes, I would re-review for arXiv readiness. The contribution itself is not the blocker. The blocker is that the current package still contains visible internal scaffolding and stale presentation artifacts that would damage credibility if posted permanently.
